New UK-wide strangles alert scheme launched today

Intervacc AB (publ) today announces the launch of a UK-wide strangles alert scheme, initiated by the company. The scheme has been developed by the Equine Infectious Disease Surveillance (EIDS) team at the University of Cambridge in collaboration with JData.

Strangles, a potentially lethal infection caused by *Streptococcus equi,* is the most frequently diagnosed infectious disease of horses worldwide. The EIDS team at the University of Cambridge works with stakeholders across the UK equine industry to support the surveillance, control and prevention of equine infectious diseases, including strangles.

Increase in reported strangles diagnoses

The Cambridge team have operated the Surveillance of Equine Strangles network, which provides an overview of strangles diagnoses dating back to 2015. Recent analysis reported the emergence of a new strain of S. equi, which is believed to be responsible for a surge in strangles diagnoses, with 937 reported in the past two years across 83 different regions of the UK, corresponding to an average of 9 reports each week. The new weekly alert scheme will provide vets and other stakeholders with updates on which UK regions had a confirmed diagnosis of strangles so that stakeholders can implement enhanced control measures to minimize the risk of further disease spread.

"The bacteria that cause strangles are highly contagious and the infection is spread via contact with infected horses or contaminated food, water or equipment" says Andrew Waller, CSO of Intervacc. *"This new alert scheme will help veterinarians and other stakeholders identify whether strangles has been reported in their local area or in regions to or from which horses are being transported. This information can support timely measures to help reduce the risk of disease spread."*

" We are very pleased to have initiated the new strangles alert scheme and look forward to supporting similar initiatives in other countries,", says Carl-Johan Dalsgaard, CEO of Intervacc. "*By providing greater visibility of where strangles is occurring, the scheme can help veterinarians identify areas of increased risk and take preventive action, including vaccination."*

For more information please contact:

Carl-Johan Dalsgaard, CEO
Phone: +46 (0)8 120 10 600
Email: carl-johan.dalsgaard@intervacc.se

The information was submitted for publication, through the agency of the contact person above, on 16 November 2026 at 08:00 CET.

About Strangvac®

Strangvac® is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

About Intervacc

Intervacc AB is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see intervacc.se

Contact information for Certified Adviser

Eminova Fondkommission AB
Email: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10